HRP20170247T1 - Biciklični spojevi - Google Patents

Biciklični spojevi

Info

Publication number
HRP20170247T1
HRP20170247T1 HRP20170247TT HRP20170247T HRP20170247T1 HR P20170247 T1 HRP20170247 T1 HR P20170247T1 HR P20170247T T HRP20170247T T HR P20170247TT HR P20170247 T HRP20170247 T HR P20170247T HR P20170247 T1 HRP20170247 T1 HR P20170247T1
Authority
HR
Croatia
Prior art keywords
bicyclic compounds
bicyclic
compounds
Prior art date
Application number
HRP20170247TT
Other languages
English (en)
Croatian (hr)
Inventor
T. G. Murali Dhar
Hai-Yun Xiao
Alaric J. Dyckman
Eric J. Chan
Marta Dabros
Daniel Richard Roberts
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20170247T1 publication Critical patent/HRP20170247T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/18Polycyclic aromatic halogenated hydrocarbons
    • C07C25/22Polycyclic aromatic halogenated hydrocarbons with condensed rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/657Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings
    • C07C49/665Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system
    • C07C49/67Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system having two rings, e.g. tetralones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/117Esters of phosphoric acids with cycloaliphatic alcohols
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20170247TT 2013-02-21 2014-02-21 Biciklični spojevi HRP20170247T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361767531P 2013-02-21 2013-02-21
PCT/US2014/017534 WO2014130752A2 (en) 2013-02-21 2014-02-21 Bicyclic compounds
EP14709822.2A EP2958888B1 (en) 2013-02-21 2014-02-21 Bicyclic compounds

Publications (1)

Publication Number Publication Date
HRP20170247T1 true HRP20170247T1 (hr) 2017-04-07

Family

ID=50272738

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170247TT HRP20170247T1 (hr) 2013-02-21 2014-02-21 Biciklični spojevi

Country Status (34)

Country Link
US (3) US9115054B2 (enExample)
EP (1) EP2958888B1 (enExample)
JP (1) JP6277210B2 (enExample)
KR (1) KR102242265B1 (enExample)
CN (1) CN105026362B (enExample)
AR (1) AR094851A1 (enExample)
AU (1) AU2014218883B2 (enExample)
BR (1) BR112015019919A2 (enExample)
CA (1) CA2902168C (enExample)
CL (1) CL2015002358A1 (enExample)
CY (1) CY1118641T1 (enExample)
DK (1) DK2958888T3 (enExample)
EA (1) EA025294B1 (enExample)
ES (1) ES2613262T3 (enExample)
HR (1) HRP20170247T1 (enExample)
HU (1) HUE031626T2 (enExample)
IL (1) IL240613B (enExample)
LT (1) LT2958888T (enExample)
MA (1) MA38425B1 (enExample)
MX (1) MX2015010347A (enExample)
MY (1) MY173990A (enExample)
PE (1) PE20151746A1 (enExample)
PH (1) PH12015501793A1 (enExample)
PL (1) PL2958888T3 (enExample)
PT (1) PT2958888T (enExample)
RS (1) RS55703B1 (enExample)
SG (1) SG11201506408TA (enExample)
SI (1) SI2958888T1 (enExample)
SM (2) SMT201700115T1 (enExample)
TN (1) TN2015000356A1 (enExample)
TW (1) TWI613182B (enExample)
UY (1) UY35338A (enExample)
WO (1) WO2014130752A2 (enExample)
ZA (1) ZA201506965B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6617702B2 (ja) 2013-07-15 2019-12-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Fty720のアザサイクリック拘束アナログ
TWI689487B (zh) 2014-08-20 2020-04-01 美商必治妥美雅史谷比公司 經取代雙環化合物
EP3352753A4 (en) * 2015-09-24 2019-03-13 The Regents of The University of California SYNTHETIC SPHINGOLIPIDE-SIMILAR MOLECULES, MEDICAMENTS, METHODS FOR THEIR SYNTHESIS AND TREATMENT PROCEDURES
WO2018045149A1 (en) 2016-09-02 2018-03-08 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Oxime ether compounds
US11046646B2 (en) 2017-08-09 2021-06-29 Bristol-Myers Squibb Company Alkylphenyl compounds
WO2021062168A1 (en) * 2019-09-25 2021-04-01 The Regents Of The University Of California Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
AU2003216054B2 (en) 2002-01-18 2007-01-04 Merck & Co., Inc. Selective S1P1/Edg1 receptor agonists
AU2003207567B2 (en) 2002-01-18 2008-01-24 Merck Sharp & Dohme Corp. Edg receptor agonists
JP4709488B2 (ja) 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Edg受容体作動薬としてのN−(ベンジル)アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
CA2477423A1 (en) 2002-03-01 2003-09-12 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
JP2005533058A (ja) 2002-06-17 2005-11-04 メルク エンド カムパニー インコーポレーテッド Edg受容体アゴニストとしての1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)アゼチジン−3−カルボキシラートおよび1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)ピロリジン−3−カルボキシラート
AU2004251146A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
CN1894225A (zh) 2003-12-17 2007-01-10 默克公司 作为鞘氨醇1-磷酸(内皮分化基因)受体激动剂的(3,4-二取代)丙酸酯
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
CN101043887A (zh) 2004-10-22 2007-09-26 默克公司 用作s1p受体激动剂的2-(芳基)氮杂环甲基羧酸酯、磺酸酯、膦酸酯、次膦酸酯和杂环化合物
JP2008530135A (ja) 2005-02-14 2008-08-07 ユニバーシティ オブ バージニア パテント ファンデーション アミノ基およびフェニル基で置換されたシクロアルカンならびに5員の複素環を含むスフィンゴシン=1−リン酸アゴニスト
CN101193852A (zh) 2005-02-18 2008-06-04 因诺迪亚有限公司 4-羟基异亮氨酸类似物及其用途
AU2006222563A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
DE602006003642D1 (en) 2005-03-23 2008-12-24 Actelion Pharmaceuticals Ltd Neue thiophen-derivate als sphingosin-1-phosphat-1-rezeptorantagonisten
CA2605594A1 (en) 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited Heterocyclic compound
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
RU2008110949A (ru) 2005-08-23 2009-09-27 Айрм Ллк (Bm) Соединения и композиции-иммуносупрессанты
CA2636324C (en) 2006-01-06 2012-03-20 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
EP1986623A2 (en) 2006-01-27 2008-11-05 University Of Virginia Patent Foundation Method for treatment of neuropathic pain
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
CA2646469A1 (en) 2006-03-21 2007-09-27 Epix Delaware, Inc. S1p receptor modulating compounds
CA2645639A1 (en) 2006-03-23 2007-10-04 Merck & Co. Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
AU2007236707C1 (en) 2006-04-03 2012-05-24 Astellas Pharma Inc. Hetero compound
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
AR062684A1 (es) 2006-09-08 2008-11-26 Actelion Pharmaceuticals Ltd Compuestos derivados de piridin-3- ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos
CN101610674A (zh) * 2006-12-21 2009-12-23 艾博特公司 鞘氨醇-1-磷酸酯受体激动剂和拮抗剂化合物
AU2007338700A1 (en) * 2006-12-21 2008-07-03 Abbott Laboratories Sphingosine-1 -phosphate receptor agonist and antagonist compounds
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
US8217027B2 (en) 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
NZ578260A (en) 2007-02-02 2012-02-24 Hoffmann La Roche Novel 2-aminooxazolines as taar1 ligands for cns disorders
DK2125797T3 (da) 2007-03-16 2014-02-10 Actelion Pharmaceuticals Ltd Aminopyridinderivater som s1p1/edg1-receptoragonister
EP2193125B1 (en) 2007-10-04 2017-01-11 Merck Serono S.A. Oxadiazole derivatives
ES2449749T3 (es) 2007-11-01 2014-03-21 Actelion Pharmaceuticals Ltd. Nuevos derivados de pirimidina
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
EP2280933B1 (en) 2008-04-01 2013-07-24 Theravance, Inc. 2 -aminotetralin derivatives as mu opioid receptor antagonists
WO2010042998A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
EA201170828A1 (ru) 2008-12-18 2011-12-30 Мерк Сероно С.А. Конденсированные гетероциклические производные оксадиазола, подходящие для лечения рассеянного склероза
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
CN102361869A (zh) * 2009-01-23 2012-02-22 百时美施贵宝公司 在治疗自身免疫性疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物
JP2012515789A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー スフィンゴシン−1−リン酸アゴニストとしてのピラゾール−1,2,4−オキサジアゾール誘導体
EP2382212B1 (en) 2009-01-23 2014-07-16 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
MX2011008458A (es) 2009-02-10 2011-09-01 Abbott Lab Metodos para preparar agonistas y antagonistas del receptor s1p.
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
ES2759949T3 (es) 2009-10-29 2020-05-12 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos
WO2011133734A1 (en) 2010-04-23 2011-10-27 Bristol-Myers Squibb Company 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists
CN102260177A (zh) 2010-05-25 2011-11-30 中国医学科学院药物研究所 丙二醇类衍生物、其制备方法和其药物组合物与用途
CN102260178A (zh) 2010-05-25 2011-11-30 中国医学科学院药物研究所 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途
CN103124727B (zh) 2010-07-20 2015-03-25 百时美施贵宝公司 取代的3-苯基-1,2,4-噁二唑化合物
CN103237795B (zh) 2010-09-24 2015-10-21 百时美施贵宝公司 经取代的噁二唑化合物及其作为s1p1激动剂的用途
EP2635573B1 (en) 2010-11-03 2014-10-01 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
EP2685971A4 (en) * 2011-03-18 2014-01-22 Univ Virginia Patent Found COMPOSITIONS AND METHODS FOR TISSUE PROCESSING AND CELL-BASED THERAPIES
WO2012147311A1 (ja) 2011-04-26 2012-11-01 パナソニック株式会社 暖房システム及び暖房システム制御方法
GB201107325D0 (en) * 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
ES2758841T3 (es) 2011-05-13 2020-05-06 Celgene Int Ii Sarl Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
NZ703851A (en) 2012-07-27 2017-01-27 Biogen Ma Inc Compounds that are s1p modulating agents and/or atx modulating agents

Also Published As

Publication number Publication date
PH12015501793B1 (en) 2015-11-09
WO2014130752A3 (en) 2014-10-23
IL240613B (en) 2018-06-28
EA025294B1 (ru) 2016-12-30
SMT201700115T1 (it) 2017-03-08
IL240613A0 (en) 2015-10-29
KR20150119352A (ko) 2015-10-23
EA201591409A1 (ru) 2015-12-30
MY173990A (en) 2020-03-03
EP2958888B1 (en) 2016-11-23
CY1118641T1 (el) 2017-07-12
US20160251309A1 (en) 2016-09-01
WO2014130752A2 (en) 2014-08-28
AR094851A1 (es) 2015-09-02
PL2958888T3 (pl) 2017-07-31
TN2015000356A1 (en) 2017-01-03
MX2015010347A (es) 2015-11-16
BR112015019919A2 (pt) 2017-07-18
US9487481B2 (en) 2016-11-08
US9359286B2 (en) 2016-06-07
US9115054B2 (en) 2015-08-25
KR102242265B1 (ko) 2021-04-19
HK1218111A1 (en) 2017-02-03
TW201444786A (zh) 2014-12-01
JP6277210B2 (ja) 2018-02-07
SG11201506408TA (en) 2015-09-29
CN105026362A (zh) 2015-11-04
AU2014218883B2 (en) 2017-05-11
TWI613182B (zh) 2018-02-01
MA38425B1 (fr) 2019-03-29
UY35338A (es) 2014-08-29
SI2958888T1 (sl) 2017-01-31
RS55703B1 (sr) 2017-07-31
AU2014218883A1 (en) 2015-10-15
US20150315128A1 (en) 2015-11-05
MA38425A1 (fr) 2017-12-29
CA2902168A1 (en) 2014-08-28
PT2958888T (pt) 2017-02-03
PE20151746A1 (es) 2015-12-02
HUE031626T2 (en) 2017-07-28
DK2958888T3 (en) 2017-03-06
US20140235591A1 (en) 2014-08-21
ZA201506965B (en) 2017-08-30
SMT201700115B (it) 2017-03-08
CN105026362B (zh) 2017-07-14
JP2016513124A (ja) 2016-05-12
LT2958888T (lt) 2017-02-10
CA2902168C (en) 2019-01-08
EP2958888A2 (en) 2015-12-30
ES2613262T3 (es) 2017-05-23
PH12015501793A1 (en) 2015-11-09
CL2015002358A1 (es) 2016-02-26

Similar Documents

Publication Publication Date Title
LT3060041T (lt) Prostaciklino junginiai
DK2970336T3 (da) Tetrahydropyrrolothiazinforbindelser
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
DK3077047T3 (da) Aramcholsalte
DK3052081T3 (da) Pastil
DK3060460T3 (da) Saddel
HRP20171890T1 (hr) Supstituirani imidazopiridazini
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
EP2970104A4 (en) BICYCLICAL ANALGETIC COMPOUNDS
DK2956698T5 (da) Bindestrimler
HRP20170247T1 (hr) Biciklični spojevi
DK2946640T3 (da) Langmuir-probe
EP2943489A4 (en) DEUTERATED MOMELOTINIB
HUE040208T2 (hu) Kéntartalmú biciklikus vegyület
IL240904A0 (en) Azetidinyloxyphenylpyrrolidine compounds
DE102013106534B8 (de) Chromatographiepipettenspitze
EP2991647A4 (en) DEUTERED AMLEXANOX
EP2970310A4 (en) 5-BROMO-indirubins
EP2853297A4 (en) kendama
HRP20180618T1 (hr) Spojevi fluorfenilpirazola
DK3071227T3 (da) Fiskevaccine
DK2947066T3 (da) Phenoxyalkylaminforbindelse
DE112014001252A5 (de) Aufbissschiene
DK3086679T3 (da) Sportssko